DNA methyltransferase 3, a target of microRNA-29c, contributes to neuronal proliferation by regulating the expression of brain-derived neurotrophic factor

Yang,Guoshuai; Song,Yanmin; Zhou,Xiaoyan; Deng,Yidong; Liu,Tao; Weng,Guohu; Yu,Dan; Pan,Suyue

doi:10.3892/mmr.2015.3531

DNA methyltransferase 3, a target of microRNA-29c, contributes to neuronal proliferation by regulating the expression of brain-derived neurotrophic factor

Authors:
- Guoshuai Yang
- Yanmin Song
- Xiaoyan Zhou
- Yidong Deng
- Tao Liu
- Guohu Weng
- Dan Yu
- Suyue Pan
View Affiliations

Affiliations: Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Neurology, Haikou People's Hospital, Haikou, Hainan 570208, P.R. China
Published online on: March 23, 2015 https://doi.org/10.3892/mmr.2015.3531
Pages: 1435-1442

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alzheimer's disease (AD), the most common form of dementia in the aged population, presents an increasing clinical challenge in terms of diagnosis and treatment. Neurodegeneration is one of the hallmarks of AD, which consequently induces cognitive impairment. Brain‑derived neurotrophic factor (BDNF), a neuroprotective factor, has been implicated in neuronal survival and proliferation. The epigenetic mechanism of BDNF methylation may be responsible for the reduced expression of BDNF in patients with AD. DNA methyltransferase may contribute to the methylation of BDNF, which is involved in neuroprotection in AD. In addition, epigenetic modifications, including a combination of microRNAs (miRNAs/miRs) and DNA methylation, have been suggested as regulatory mechanisms in the control of neuronal survival. In the present study, the expression of miR‑29c was determined in the cerebrospinal fluid (CSF) of patients with AD and of healthy control individuals. A marked decrease in the expression of miR‑29c was observed in the AD group compared with the normal control group, accompanied by a decreased in the expression of BDNF. Additionally, a significant increase in the expression of DNA methyltransferase 3 (DNMT3) was observed in the CSF from the patients with AD. Correlation analysis revealed that the expression of miR‑29c was positively correlated with BDNF and negatively correlated with DNMT3 protein in the CSF of patients with AD. In addition, the regulatory association between miR‑29c, DNMT3 and BDNF were also examined in vitro. It was demonstrated that miR‑29c directly targeted DNMT3 and contributed to neuronal proliferation by regulating the expression of BDNF, at least partially, through enhancing the activity of the tyrosine receptor kinase B/extracellular signal‑regulated kinase signaling pathway. In conclusion, the present study suggested that miR‑29c may be a promising potential therapeutic target in the treatment of AD.

View Figures

View References

1	Kim DH, Yeo SH, Park JM, et al: Genetic markers for diagnosis and pathogenesis of Alzheimer’s disease. Gene. 545:185–193. 2014. View Article : Google Scholar : PubMed/NCBI
2	Morales I, Guzmán-Martínez L, Cerda-Troncoso C, Farías GA and Maccioni RB: Neuroinflammation in the pathogenesis of Alzheimer’s disease A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci. 8:1122014. View Article : Google Scholar
3	Dunkel P, Chai CL, Sperlágh B, Huleatt PB and Mátyus P: Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases and amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 21:1267–1308. 2012. View Article : Google Scholar : PubMed/NCBI
4	García-Mesa Y, Pareja-Galeano H, Bonet-Costa V, et al: Physical exercise neuroprotects ovariectomized 3xTg-AD mice through BDNF mechanisms. Psychoneuroendocrinology. 45:154–166. 2014. View Article : Google Scholar : PubMed/NCBI
5	Li G, Peskind ER, Millard SP, et al: Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One. 4:e54242009. View Article : Google Scholar : PubMed/NCBI
6	Keleshian VL, Modi HR, Rapoport SI and Rao JS: Aging is associated with altered inflammatory, arachidonic acid cascade and synaptic markers, influenced by epigenetic modifications, in the human frontal cortex. J Neurochem. 125:63–73. 2013. View Article : Google Scholar : PubMed/NCBI
7	Walker MP, LaFerla FM, Oddo SS and Brewer GJ: Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer’s disease. Age (Dordr). 35:519–531. 2013. View Article : Google Scholar
8	Mastroeni D, Chouliaras L, Grover A, et al: Reduced RAN expression and disrupted transport between cytoplasm and nucleus; a key event in Alzheimer’s disease pathophysiology. PLoS One. 8:e533492013. View Article : Google Scholar
9	Bihaqi SW, Huang H, Wu J and Zawia NH: Infant exposure to lead (Pb) and epigenetic modifications in the aging primate brain: implications for Alzheimer’s disease. J Alzheimers Dis. 27:819–833. 2011.
10	Fuso A, Nicolia V, Cavallaro RA and Scarpa S: DNA methylase and demethylase activities are modulated by one-carbon metabolism in Alzheimer’s disease models. J Nutr Biochem. 22:242–251. 2011. View Article : Google Scholar
11	Imai S, Saeki M, Yanase M, et al: Change in microRNAs associated with neuronal adaptive responses in the nucleus accumbens under neuropathic pain. J Neurosci. 31:15294–15299. 2011. View Article : Google Scholar : PubMed/NCBI
12	Pereira P, Sousa Â, Queiroz J, Correia I, Figueiras A and Sousa F: Purification of pre-miR-29 by arginine-affinity chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 951–952:16–23. 2014. View Article : Google Scholar
13	Zhang J, Hu M, Teng Z, Tang YP and Chen C: Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188–3p in a mouse model of Alzheimer’s disease. J Neurosci. 34:14919–14933. 2014. View Article : Google Scholar : PubMed/NCBI
14	Kong Y, Wu J and Yuan L: MicroRNA expression analysis of adult-onset Drosophila Alzheimer’s disease model. Curr Alzheimer Res. 11:882–891. 2014.
15	Pogue AI, Hill JM and Lukiw WJ: MicroRNA (miRNA): Sequence and stability, viroid-like properties and disease association in the CNS. Brain Res. 1584:73–79. 2014. View Article : Google Scholar : PubMed/NCBI
16	Spencer P, Fry RC and Kisby GE: Unraveling 50-year-old Clues linking Neurodegeneration and cancer to Cycad Toxins: Are microRNAs common mediators? Front Genet. 3:1922012. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
18	Harvey PD: Clinical applications of neuropsychological assessment. Dialogues Clin Neurosci. 14:91–99. 2012.PubMed/NCBI
19	Lista S, Zetterberg H, Dubois B, Blennow K and Hampel H: Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments. J Neurol. 261:1234–1243. 2014. View Article : Google Scholar : PubMed/NCBI
20	Peng S, Wuu J, Mufson EJ and Fahnestock M: Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem. 93:1412–1421. 2005. View Article : Google Scholar : PubMed/NCBI
21	Laske C, Stellos K, Hoffmann N, et al: Higher BDNF serum levels predict slower cognitive decline in Alzheimer’s disease patients. Int J Neuropsychopharmacol. 14:399–404. 2011. View Article : Google Scholar
22	Laske C, Stransky E, Leyhe T, et al: BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res. 41:387–394. 2007. View Article : Google Scholar
23	Subramaniam D, Thombre R, Dhar A and Anant S: DNA Methyltransferases: a novel target for prevention and therapy. Front Oncol. 4:802014. View Article : Google Scholar : PubMed/NCBI
24	Boersma GJ, Lee RS, Cordner ZA, et al: Prenatal stress decreases Bdnf expression and increases methylation of Bdnf exon IV in rats. Epigenetics. 9:437–447. 2014. View Article : Google Scholar :
25	Guo X, Wu X, Ren L, Liu G and Li L: Epigenetic mechanisms of amyloid-beta production in anisomycin-treated SH-SY5Y cells. Neuroscience. 194:272–281. 2011. View Article : Google Scholar : PubMed/NCBI
26	Zhang J, Sokal I, Peskind ER, et al: CSF multianalyte profile distinguishes Alzheimer and Parkinson disease. Am J Clin Pathol. 129:526–529. 2008. View Article : Google Scholar : PubMed/NCBI
27	Kiko T, Nakagawa K, Tsuduki T, Furukawa K, Arai H and Miyazawa T: MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease. J Alzheimers Dis. 39:253–259. 2014.
28	Wang WX, Huang Q, Hu Y, Stromberg AJ and Nelson PT: Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: white matter versus gray matter. Acta Neuropathol. 121:193–205. 2011. View Article : Google Scholar :
29	Pandey M, Sultana S and Gupta KP: Involvement of epigenetics and microRNA-29b in the urethane induced inception and establishment of mouse lung tumors. Exp Mol Pathol. 96:61–70. 2014. View Article : Google Scholar
30	Tong L, Balazs R, Thornton PL and Cotman CW: Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci. 24:6799–6809. 2004. View Article : Google Scholar : PubMed/NCBI
31	Jeronimo-Santos A, Vaz SH, Parreira S, et al: Dysregulation of TrkB receptors and BDNF function by Amyloid-β Peptide is mediated by Calpain. Cereb Cortex. 2014. View Article : Google Scholar
32	Liu Y, Tao L, Fu X, Zhao Y and Xu X: BDNF protects retinal neurons from hyperglycemia through the TrkB/ERK/MAPK pathway. Mol Med Rep. 7:1773–1778. 2013.PubMed/NCBI